Case number 1:21-cv-00248
Aether Therapeutics Inc. v. RedHill Biopharma Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 10, 2023 | 217 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulation of Dismissal)(mdb) (Entered: 04/10/2023) (Main Document) (1) |
| Apr 10, 2023 | 217 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulation of Dismissal)(mdb) (Entered: 04/10/2023) (Stipulation of Dismissal) (2) |
| Apr 6, 2023 | 215 | STIPULATION of Dismissal with Prejudice by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) Modified on 4/6/2023 (dlw). (Entered: 04/06/2023) (2) |
| Apr 6, 2023 | 216 | SO ORDERED re (260 in 1:20-cv-00381-MN, 215 in 1:21-cv-00248-MN) Stipulation of Dismissal ***Civil Case Terminated. Signed by Judge Maryellen Noreika on 4/6/2023. (dlw) (Entered: 04/06/2023) (2) |
| Mar 31, 2023 | 214 | [SEALED] Joint MOTION to Stay for Twenty-One Days - filed by Aether Therapeutics Inc. (Stamoulis, Stamatios) Modified on 3/31/2023 (dlw). (Entered: 03/31/2023) (0) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Main Document) (25) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 1) (5) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 2) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 3) (4) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 4) (18) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 5) (7) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 6) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 7) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 7A) (2) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 8) (15) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 9) (22) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 10) (17) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 11) (19) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 12) (5) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 13) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 14) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 15) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 16) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 17) (30) |
| Mar 14, 2023 | 213 | REDACTED VERSION of (203 in 1:21-cv-00248-MN, 248 in 1:20-cv-00381-MN) Proposed Order by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 7A, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16, # 18 Exhibit 17, # 19 Exhibit 18)(Stamoulis, Stamatios) (Entered: 03/14/2023) (Exhibit 18) (30) |
| Mar 13, 2023 | 212 | STIPULATION TO EXTEND TIME the Deadline to Submit a Public Redacted Version of Joint Proposed Pretrial Order to March 15, 2023 - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) (Entered: 03/13/2023) (2) |
| Mar 10, 2023 | 211 | REDACTED VERSION of (254 in 1:20-cv-00381-MN, 209 in 1:21-cv-00248-MN) Stipulation by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) Modified on 3/10/2023 (dlw). (Entered: 03/10/2023) (2) |
| Mar 6, 2023 | 210 | STIPULATION TO EXTEND TIME the Deadline to Submit a Public Redacted Version of Joint Proposed Pretrial Order to March 13, 2023 - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) (Entered: 03/06/2023) (2) |
| Feb 28, 2023 | 209 | [SEALED] STIPULATION Staying Litigation For 30 Days -- See Stipulation For Details by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Silver, Daniel) (Entered: 02/28/2023) (0) |
| Feb 27, 2023 | 203 | [SEALED] Joint PROPOSED ORDER Pretrial by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1-15, # 2 Exhibit 16-18)(Stamoulis, Stamatios) (Entered: 02/27/2023) (0) |
| Feb 27, 2023 | 204 | Proposed PRELIMINARY Jury Instructions by Aether Therapeutics Inc. (Stamoulis, Stamatios) Modified on 2/28/2023 (dlw). (Entered: 02/27/2023) (25) |
| Feb 27, 2023 | 205 | Proposed FINAL Jury Instructions by Aether Therapeutics Inc. (Stamoulis, Stamatios) Modified on 2/28/2023 (dlw). (Entered: 02/27/2023) (30) |
| Feb 27, 2023 | 206 | Proposed Voir Dire by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 02/27/2023) (8) |
| Feb 27, 2023 | 207 | Defendants' Proposed VERDICT SHEET by Aether Therapeutics Inc. (Stamoulis, Stamatios) Modified on 2/28/2023 (dlw). (Entered: 02/27/2023) (8) |
| Feb 27, 2023 | 208 | Plaintiff's Proposed VERDICT SHEET by Aether Therapeutics Inc. (Stamoulis, Stamatios) Modified on 2/28/2023 (dlw). (Entered: 02/27/2023) (7) |
| Feb 22, 2023 | 202 | ANSWERING BRIEF in Opposition re 189 MOTION for Summary Judgment filed by Aether Therapeutics Inc..Reply Brief due date per Local Rules is 3/1/2023. (Attachments: # 1 Exhibit A-Q)(Stamoulis, Stamatios) (Entered: 02/22/2023) (Main Document) (14) |
| Feb 22, 2023 | 202 | ANSWERING BRIEF in Opposition re 189 MOTION for Summary Judgment filed by Aether Therapeutics Inc..Reply Brief due date per Local Rules is 3/1/2023. (Attachments: # 1 Exhibit A-Q)(Stamoulis, Stamatios) (Entered: 02/22/2023) (Exhibit A-Q) (30) |
| Feb 21, 2023 | 201 | ORAL ORDER Setting Mediation Conferences: A Telephonic Mediation Conference is set for 2/24/2023 at 10:30 AM before Judge Mary Pat Thynge. Plaintiff shall provide a joint telephonic conference line and a separate telephonic conference line for private discussions solely with plaintiff/plaintiff's counsel. Defense counsel shall provide a separate telephonic conference line for the defendants/defense counsel's private discussions. Dial in information shall be provided by no later than 2/23/2023 by 10:30 AM Eastern time. In addition, each side shall exchange and provide to Judge Thynge the identities/titles of their client representative(s) who have settlement authority and must attend. The telephonic mediation discussion shall be initiated by plaintiff's counsel on the joint telephonic conference line at 10:30 AM Eastern time on Friday, 2/24/2023. A copy of this information shall be provided directly to Judge Mary Pat Thynge. Signed by Judge Mary Pat Thynge on 02/21/2023. Associated Cases: 1:20-cv-00381-MN, 1:21-cv-00248-MN(rlla) (Entered: 02/21/2023) (0) |
| Feb 20, 2023 | 200 | MOTION for Pro Hac Vice Appearance of Attorney Paul S. Danner and Emma L. Freedenburg - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 02/20/2023) (6) |
| Feb 17, 2023 | 198 | ORAL ORDER: This case is referred to Chief Magistrate Judge Thynge for the purpose of exploring ADR. ORDERED by Judge Maryellen Noreika on 2/17/2023. Associated Cases: 1:20-cv-00381-MN, 1:21-cv-00248-MN(mdb) (Entered: 02/17/2023) (0) |
| Feb 17, 2023 | 199 | ORAL ORDER: Pursuant to the February 17, 2023 Order referring this matter for the purpose of exploring ADR [D.I. 242 in C.A. No. 20-381; D.I. 198 in C.A. No. 21-248], IT IS HEREBY ORDERED that on or before 4 PM on Wednesday, February 22, 2023, each party shall hand-deliver to Judge Thynge's chambers a submission of no more than 3 pages double-spaced containing the information specified in paragraphs 6(e), (f) and (g) of Judge Thynge's Order Governing In-Person or Video Conference Mediation and Mediation Statements. Ordered by Judge Mary Pat Thynge on 2/17/2023. Associated Cases: 1:20-cv-00381-MN, 1:21-cv-00248-MN (Entered: 02/17/2023) (0) |
| Feb 15, 2023 | 197 | ORAL ORDER: The Court did not rule that the cases are consolidated for all purposes including trial. THEREFORE IT IS HEREBY ORDERED THAT the February 3, 2023 Minute Entry and the February 15, 2023 Remark are corrected to delete references to consolidation. Both AstraZeneca and Red Hill, however, should be prepared to go to trial during the time set forth in the Court's Scheduling Order in C.A. 20-381. ORDERED by Judge Maryellen Noreika on 2/15/2023. Associated Cases: 1:20-cv-00381-MN, 1:21-cv-00248-MN(mdb) (Entered: 02/15/2023) (0) |
| Feb 14, 2023 | 195 | Official Transcript of Markman Hearing held on 02/03/2023 before Judge Maryellen Noreika. Court Reporter/Transcriber Dale C. Hawkins,Email: Dale_Hawkins@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/7/2023. Redacted Transcript Deadline set for 3/17/2023. Release of Transcript Restriction set for 5/15/2023. (dh) (Entered: 02/14/2023) (103) |
| Feb 14, 2023 | 196 | MEMORANDUM ORDER REGARDING SUPPLEMENTAL CLAIM CONSTRUCTION. Signed by Judge Maryellen Noreika on 2/14/2023. (dlw) (Entered: 02/14/2023) (10) |
| Feb 10, 2023 | 193 | NOTICE OF SERVICE of Defendants' Notice Pursuant to 35 U.S.C. § 282 filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC.(Joyce, Alexandra) (Entered: 02/10/2023) (3) |
| Feb 10, 2023 | 194 | MOTION for Pro Hac Vice Appearance of Attorney Wyley S. Proctor - filed by RedHill Biopharma Inc.. (Joyce, Alexandra) (Entered: 02/10/2023) (2) |
| Feb 9, 2023 | 192 | REPLY BRIEF re 187 MOTION for Leave to File a Declaration of David W.C. MacMillan, Ph.D. filed by RedHill Biopharma Inc. (Joyce, Alexandra) Modified on 2/9/2023 (dlw). (Entered: 02/09/2023) (2) |
| Feb 8, 2023 | 187 | MOTION for Leave to File a Declaration of David W.C. MacMillan, Ph.D. - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Counsel, # 3 Exhibit A-C)(Joyce, Alexandra) Modified on 2/9/2023 (dlw). (Entered: 02/08/2023) (Main Document) (4) |
| Feb 8, 2023 | 188 | STATEMENT // Defendants' Concise Statement of Material Facts as to Which There is No Genuine Issue In Support of Their Motion for Summary Judgment by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) Modified on 2/9/2023 (dlw). (Entered: 02/08/2023) (9) |
| Feb 8, 2023 | 189 | MOTION for Summary Judgment - filed by RedHill Biopharma Inc.. (Attachments: # 1 Text of Proposed Order)(Joyce, Alexandra) (Entered: 02/08/2023) (Main Document) (2) |
| Feb 8, 2023 | 190 | OPENING BRIEF in Support re 189 MOTION for Summary Judgment filed by RedHill Biopharma Inc..Answering Brief/Response due date per Local Rules is 2/22/2023. (Attachments: # 1 Exhibit 1-12)(Joyce, Alexandra) (Entered: 02/08/2023) (Main Document) (14) |
| Feb 8, 2023 | 191 | RESPONSE to Motion re 187 MOTION for Leave to File a Declaration of David W.C. MacMillan, Ph.D. filed by Aether Therapeutics Inc. (Attachments: # 1 Exhibit A)(Stamoulis, Stamatios) Modified on 2/9/2023 (dlw). (Entered: 02/08/2023) (Main Document) (3) |
| Feb 8, 2023 | 191 | RESPONSE to Motion re 187 MOTION for Leave to File a Declaration of David W.C. MacMillan, Ph.D. filed by Aether Therapeutics Inc. (Attachments: # 1 Exhibit A)(Stamoulis, Stamatios) Modified on 2/9/2023 (dlw). (Entered: 02/08/2023) (Exhibit A) (5) |
| Feb 8, 2023 | 187 | MOTION for Leave to File a Declaration of David W.C. MacMillan, Ph.D. - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Counsel, # 3 Exhibit A-C)(Joyce, Alexandra) Modified on 2/9/2023 (dlw). (Entered: 02/08/2023) (Text of Proposed Order) (1) |
| Feb 8, 2023 | 187 | MOTION for Leave to File a Declaration of David W.C. MacMillan, Ph.D. - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Counsel, # 3 Exhibit A-C)(Joyce, Alexandra) Modified on 2/9/2023 (dlw). (Entered: 02/08/2023) (Certification of Counsel) (1) |
| Feb 8, 2023 | 187 | MOTION for Leave to File a Declaration of David W.C. MacMillan, Ph.D. - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Counsel, # 3 Exhibit A-C)(Joyce, Alexandra) Modified on 2/9/2023 (dlw). (Entered: 02/08/2023) (Exhibit A-C) (11) |
| Feb 8, 2023 | 190 | OPENING BRIEF in Support re 189 MOTION for Summary Judgment filed by RedHill Biopharma Inc..Answering Brief/Response due date per Local Rules is 2/22/2023. (Attachments: # 1 Exhibit 1-12)(Joyce, Alexandra) (Entered: 02/08/2023) (Exhibit 1-12) (30) |
| Feb 8, 2023 | 189 | MOTION for Summary Judgment - filed by RedHill Biopharma Inc.. (Attachments: # 1 Text of Proposed Order)(Joyce, Alexandra) (Entered: 02/08/2023) (Text of Proposed Order) (1) |
| Jan 4, 2023 | 185 | JOINT CLAIM CONSTRUCTION BRIEF and Indefiniteness filed by RedHill Biopharma Inc. (Joyce, Alexandra) Modified on 1/5/2023 (dlw). (Entered: 01/04/2023) (30) |
| Jan 4, 2023 | 186 | Joint APPENDIX re (185 in 1:21-cv-00248-MN) Joint Claim Construction Brief, (229 in 1:20-cv-00381-MN) Joint Claim Construction Brief by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Attachments: # 1 Exhibit 1-13)(Joyce, Alexandra) (Entered: 01/04/2023) (Main Document) (4) |
| Jan 4, 2023 | 186 | Joint APPENDIX re (185 in 1:21-cv-00248-MN) Joint Claim Construction Brief, (229 in 1:20-cv-00381-MN) Joint Claim Construction Brief by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals, LP, Nektar Therapeutics, LLC. (Attachments: # 1 Exhibit 1-13)(Joyce, Alexandra) (Entered: 01/04/2023) (Exhibit 1-13) (30) |
| Dec 21, 2022 | 184 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. - re Telephone Conference,,, Set Scheduling Order Deadlines,,, Set Trial Management Order Deadlines,,, Terminate Deadlines and Hearings,,. (Joyce, Alexandra) (Entered: 12/21/2022) (1) |
| Dec 8, 2022 | 183 | ORAL ORDER Setting Teleconference: IT IS HEREBY ORDERED that a Telephone Conference is set for 12/14/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 12/8/2022. (dlw) (Entered: 12/08/2022) (0) |
| Dec 7, 2022 | 182 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. - re (225 in 1:20-cv-00381-MN, 181 in 1:21-cv-00248-MN) Oral Order,,,,. (Silver, Daniel) (Entered: 12/07/2022) (2) |
| Dec 5, 2022 | 180 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding In-Person Hearing of January 18, 2023. (Silver, Daniel) (Entered: 12/05/2022) (1) |
| Dec 5, 2022 | 181 | ORAL ORDER re (180 in 1:21-cv-00248-MN, 224 in 1:20-cv-00381-MN) Letter - Having reviewed Defendants' December 5, 2022 letter, IT IS HEREBY ORDERED that the Court will NOT hear remote testimony in connection with the additional claim construction proceedings. If Defendants prefer to reschedule the January 18, 2023 hearing to accommodate their expert's schedule, the Court will hear the claim construction issue during the trial (either before 9:00 a.m. or after the jury leaves for the day). On or before December 7, 2022, the parties shall inform the Court if they want to keep the current date or switch to before/after trial days. IT IS FURTHER ORDERED that the parties' proposal for briefing is REJECTED. Eighty pages of briefing for one term is excessive and the Court does not wish to receive two sets of briefs. Therefore, on or before January 4, 2023, the parties shall instead file a joint claim construction brief (as is described in the Scheduling Order) of no more than 30 pages in total (15 pages for Plaintiff and 15 pages for Defendants). ORDERED by Judge Maryellen Noreika on 12/5/2022. (dlw) (Entered: 12/05/2022) (0) |
| Dec 1, 2022 | 179 | ORAL ORDER re (208, 209, 210, 216, 217, 218 in 1:20-cv-00381-MN and 164, 165, 166, 172, 173, 174 in 1:21-cv-00248-MN) - Having reviewed the parties' requests for leave to file summary judgment and Daubert motions, IT IS HEREBY ORDERED that those requests are DENIED at this time. The Court will hold an in-person hearing on 1/18/2023 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika regarding the claim construction issues surrounding the "analog" terms. The Court is setting aside 2 hours for the hearing with the time split equally between the parties. To the extent any party intends to rely on expert testimony regarding the meaning of the term or the definiteness of the term, the Court expects the expert(s) to be present and prepared to testify. On or before 12/5/2022, the parties shall submit a proposed, expedited briefing schedule for these issues with the reply brief being filed no later than 1/4/2023. IT IS FURTHER ORDERED that any slide presentations the parties wish to use during the hearing shall be emailed (in PDF format) to MN_civil@ded.uscourts.gov no later than 24 hours prior to the hearing with hard copies delivered to the Clerk's office within one (1) hour thereafter. Counsel may, however, agree upon a different time to exchange their respective slides. ORDERED by Judge Maryellen Noreika on 12/1/2022. (dlw) (Entered: 12/01/2022) (0) |
| Oct 28, 2022 | 178 | REDACTED VERSION of (174 in 1:21-cv-00248-MN, 218 in 1:20-cv-00381-MN) Letter, by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) (Entered: 10/28/2022) (9) |
| Oct 27, 2022 | 176 | REDACTED VERSION of (217 in 1:20-cv-00381-MN, 173 in 1:21-cv-00248-MN) Letter by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 10/27/2022) (30) |
| Oct 27, 2022 | 177 | REDACTED VERSION of (172 in 1:21-cv-00248-MN, 216 in 1:20-cv-00381-MN) Letter by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 10/27/2022) (30) |
| Oct 24, 2022 | 175 | STIPULATION TO EXTEND TIME to file public versions of 1) Letter Dated October 14, 2022 To The Honorable Maryellen Noreika From Stamatios Stamoulis, Esq. In Response To Defendants Request For Leave To File Daubert Motions, 2) Letter Dated October 14, 2022 To The Honorable Maryellen Noreika From Stamatios Stamoulis, Esq. In Response To Defendants Request For Leave To File A Motion For Summary Judgment, and 3) Letter Dated October 14, 2022, From Daniel M. Silver, Esq., To The Honorable Maryellen Noreika Regarding Defendants Opposition To Plaintiffs Request For Leave To File Case No. 20-381-MN Case No. 21-248-MN A Daubert Motion to October 28, 2022 - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 10/24/2022) (3) |
| Oct 14, 2022 | 170 | REDACTED VERSION of (209 in 1:20-cv-00381-MN, 165 in 1:21-cv-00248-MN) Letter by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) (Entered: 10/14/2022) (30) |
| Oct 14, 2022 | 171 | REDACTED VERSION of (210 in 1:20-cv-00381-MN, 166 in 1:21-cv-00248-MN) Letter by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) (Entered: 10/14/2022) (30) |
| Oct 14, 2022 | 172 | [SEALED] Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis regarding Responding to Defendants' Request to Fille Daubert Motions - re (165 in 1:21-cv-00248-MN) Letter. (Stamoulis, Stamatios) (Entered: 10/14/2022) (0) |
| Oct 14, 2022 | 173 | [SEALED] Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis regarding Responding to Defendant's Request to File Summary Judgment Motions - re (166 in 1:21-cv-00248-MN) Letter. (Stamoulis, Stamatios) (Entered: 10/14/2022) (0) |
| Oct 14, 2022 | 174 | [SEALED] Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Defendants' Opposition to Plaintiff's Request for Leave to File a Daubert Motion - re (164 in 1:21-cv-00248-MN, 208 in 1:20-cv-00381-MN) Letter. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Silver, Daniel) (Entered: 10/14/2022) (0) |
| Oct 13, 2022 | 169 | REDACTED VERSION of (164 in 1:21-cv-00248-MN, 208 in 1:20-cv-00381-MN) Letter No Redactions by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 10/13/2022) (30) |
| Oct 11, 2022 | 168 | REDACTED VERSION of (161 in 1:21-cv-00248-MN, 205 in 1:20-cv-00381-MN) Letter by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) (Entered: 10/11/2022) (30) |
| Oct 10, 2022 | 167 | REDACTED VERSION of (206 in 1:20-cv-00381-MN, 162 in 1:21-cv-00248-MN) Letter by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 10/10/2022) (30) |
| Oct 7, 2022 | 164 | [SEALED] Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis regarding Seeking Leave to File a Daubert Motion for MacMillan Testimony. (Stamoulis, Stamatios) (Entered: 10/07/2022) (0) |
| Oct 7, 2022 | 165 | [SEALED] Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Seeking Leave to File Daubert Motions on Behalf of Defendants. (Attachments: # 1 Exhibit A-F, # 2 Certificate of Service)(Silver, Daniel) (Entered: 10/07/2022) (0) |
| Oct 7, 2022 | 166 | [SEALED] Letter to The Honorable Maryellen Noreika from Daniel M. Silver regarding Seeking Leave to File a Motion for Summary Judgment on Behalf of Defendants. (Attachments: # 1 Exhibit A-D, # 2 Certificate of Service)(Silver, Daniel) (Entered: 10/07/2022) (0) |
| Oct 6, 2022 | 163 | ORAL ORDER: IT IS HEREBY ORDERED that the transcript of the October 6, 2022 discovery dispute teleconference shall serve as the Order of the Court. ORDERED by Judge Jennifer L. Hall on 10/6/2022. Associated Cases: 1:20-cv-00381-MN, 1:21-cv-00248-MN(ceg) (Entered: 10/06/2022) (0) |
| Oct 4, 2022 | 162 | [SEALED] Letter to the Honorable Jennifer L. Hall from Stamatios Stamoulis regarding Responding to Defendant's Dispute Letter - re (161 in 1:21-cv-00248-MN, 205 in 1:20-cv-00381-MN) Letter. (Stamoulis, Stamatios) (Entered: 10/04/2022) (0) |
| Oct 3, 2022 | 161 | [SEALED] Letter to The Honorable Jennifer L. Hall from Daniel M. Silver, Esq. regarding Discovery Disputes. (Attachments: # 1 Exhibit A-C, # 2 Text of Proposed Order, # 3 Certificate of Service)(Silver, Daniel) (Entered: 10/03/2022) (0) |
| Sep 30, 2022 | 160 | ORAL ORDER Setting Teleconference: The Court has reviewed the Motion for Teleconference to Resolve Discovery Disputes (C.A. 20-381, D.I. 203; C.A. 21-248, D.I. 159). A discovery dispute teleconference is scheduled for October 6, 2022 at 4:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than October 3, 2022, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than October 4, 2022, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Jennifer L. Hall on 9/30/2022. Associated Cases: 1:20-cv-00381-MN, 1:21-cv-00248-MN(ceg) (Entered: 09/30/2022) (0) |
| Sep 29, 2022 | 159 | MOTION for Teleconference to Resolve Discovery Disputes re (158 in 1:21-cv-00248-MN, 202 in 1:20-cv-00381-MN) Oral Order,, - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC. (Silver, Daniel) (Entered: 09/29/2022) (3) |
| Sep 23, 2022 | 158 | ORAL ORDER - Consistent with the Scheduling Order, on 9/23/2022, the parties contacted Chambers to request a teleconference date for disputes regarding an expert report, IT IS HEREBY ORDERED that these disputes are referred to Magistrate Judge Hall. The parties are directed file Magistrate Judge Hall's "Motion for Teleconference to Resolve Discovery/Protective Order Disputes" which can be found at https://www.ded.uscourts.gov/judge/magistrate-judge-jennifer-l-hall, forms. ORDERED by Judge Maryellen Noreika on 9/23/2022. (dlw) (Entered: 09/23/2022) (0) |
| Sep 21, 2022 | 156 | NOTICE requesting Clerk to remove April Abele Isaacson, Courtney S. Dabbiere, Gabrielle Markeson, Brian D. OReilly, Christopher P. Damitio, and Kasey E. Koballa as co-counsel.. (Silver, Daniel) (Entered: 09/21/2022) (1) |
| Sep 21, 2022 | 157 | NOTICE to Take Deposition of David W.C. MacMillian on September 21, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 09/21/2022) (3) |
| Sep 16, 2022 | 154 | NOTICE OF SERVICE of Reply Report of Dr. David W.C. MacMillan, Ph.D. filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC.(Joyce, Alexandra) (Entered: 09/16/2022) (3) |
| Sep 16, 2022 | 155 | NOTICE OF SERVICE of reply expert reports from Dr. Thomas E. Prisinzano and Dr. Jeffrey Stec filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 09/16/2022) (2) |
| Sep 13, 2022 | 152 | NOTICE to Take Deposition of Dr. Jeffery A. Stec on September 22, 2022 filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Nektar Therapeutics, LLC.(Joyce, Alexandra) (Entered: 09/13/2022) (3) |
| Sep 13, 2022 | 153 | NOTICE to Take Deposition of Dr. Thomas E. Prisinzano on September 28, 2022 filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC.(Joyce, Alexandra) (Entered: 09/13/2022) (3) |
| Sep 9, 2022 | 150 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Joint Status Report. (Silver, Daniel) (Entered: 09/09/2022) (3) |
| Sep 9, 2022 | 151 | NOTICE OF SERVICE of Aether Therapeutics, Inc.s Third Supplemental Infringement Contentions for U.S. Patent No. 6,713,488 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 09/09/2022) (2) |
| Aug 29, 2022 | 149 | NOTICE OF SERVICE of (1) Responsive Report of Dr. David W.C. MacMillan, Ph.D. Regarding Non-Infringement of U.S. Patent No. 6,713,488 and (2) Rebuttal Expert Report of Carla S. Mulhern filed by Aether Therapeutics Inc..(Silver, Daniel) (Entered: 08/29/2022) (3) |
| Aug 26, 2022 | 147 | STIPULATION TO EXTEND TIME the parties' deadline to submit a joint status report to September 9, 2022 - filed by RedHill Biopharma Inc.. (Joyce, Alexandra) (Entered: 08/26/2022) (1) |
| Aug 26, 2022 | 148 | NOTICE OF SERVICE of Rebuttal Expert Report of Dr. Thomas E. Prisinzano Regarding Invalidity of U.S. Patent No. 6,713,488 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 08/26/2022) (2) |
| Aug 10, 2022 | 146 | NOTICE OF SERVICE of expert reports from Dr. Thomas E. Prisinzano and Dr. Jeffrey Stec filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 08/10/2022) (2) |
| Aug 5, 2022 | 145 | NOTICE OF SERVICE of Opening Report of Dr. David W.C. MacMillan, Ph.D. filed by Aether Therapeutics Inc..(Joyce, Alexandra) (Entered: 08/05/2022) (4) |
| Jul 15, 2022 | 143 | Joint Letter to The Honorable Maryellen Noreika from the Parties regarding Court's March 7, 2022 Orders Regarding Claim Construction Issues After Service of Final Contentions. (Silver, Daniel) (Entered: 07/15/2022) (3) |
| Jul 15, 2022 | 144 | STIPULATION TO EXTEND TIME to amend schedule regarding expert discovery to various dates - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 07/15/2022) (4) |
| Jul 8, 2022 | 142 | NOTICE OF SERVICE of Defendants AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, and RedHill Biopharma Inc.'s Final Invalidity Contentions filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC.(Silver, Daniel) (Entered: 07/08/2022) (4) |
| Jun 24, 2022 | 141 | NOTICE OF SERVICE of Aether Therapeutics Inc.s Second Supplemental Infringement Contentions for U.S. Patent No. 6,713,488 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 06/24/2022) (2) |
| Jun 10, 2022 | 140 | NOTICE OF SERVICE of Amended Subpoenas and Notice of Deposition of Dr. Yancey-Wrona filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC.(Joyce, Alexandra) (Entered: 06/10/2022) (9) |
| Jun 7, 2022 | 139 | NOTICE to Take Deposition of Michael Bentley on June 16, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 06/07/2022) (3) |
| Jun 3, 2022 | 138 | NOTICE to Take Deposition of Kevin Brodbeck on June 8, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 06/03/2022) (4) |
| Jun 1, 2022 | 136 | NOTICE to Take Deposition of Catherine Datto on June 23, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 06/01/2022) (3) |
| Jun 1, 2022 | 137 | NOTICE to Take Deposition of Brandon Rawding on June 7, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 06/01/2022) (4) |
| May 27, 2022 | 135 | NOTICE to Take Deposition of Danielle Abramson on June 9, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 05/27/2022) (4) |
| May 25, 2022 | 134 | NOTICE OF SERVICE of Defendants AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, and RedHill Biopharma Inc.'s Supplemental Identification of Invalidity References filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC.(Joyce, Alexandra) (Entered: 05/25/2022) (4) |
| May 24, 2022 | 133 | NOTICE of Withdrawal of Depositions by Aether Therapeutics Inc. (Stamoulis, Stamatios) (Entered: 05/24/2022) (3) |
| May 23, 2022 | 132 | NOTICE to Take Deposition of Jennifer Riggs-Sauthier on May 26, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 05/23/2022) (4) |
| May 13, 2022 | 129 | Amended NOTICE of Deposition of Wolfgang Sadee by RedHill Biopharma Inc. (Joyce, Alexandra) (Entered: 05/13/2022) (2) |
| May 13, 2022 | 130 | STIPULATION TO EXTEND TIME Defendants' Deadline to Supplement the Identification of All Invalidity References to May 24, 2022 - filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Nektar Therapeutics, LLC. (Joyce, Alexandra) (Entered: 05/13/2022) (3) |
| May 13, 2022 | 131 | NOTICE OF SERVICE of Redhill Biopharma Inc.'s First Supplemental Responses and Objections to Aether Therapeutics Inc.'s First Set of Interrogatories (No. 3) filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 05/13/2022) (2) |
| May 5, 2022 | 128 | NOTICE OF SERVICE of Amended Suboenas and Notice of Deposition of Laura Bohn filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 05/05/2022) (13) |
| May 2, 2022 | 126 | NOTICE to Take Deposition of Rick Scruggs on May 11, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 05/02/2022) (4) |
| May 2, 2022 | 127 | NOTICE to Take Deposition of Designated Corporation Representative(s) of Defendant Redhill Biopharma Inc. on May 11, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 05/02/2022) (16) |
| Apr 22, 2022 | 125 | NOTICE OF SERVICE of Defendant's First Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-8) filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 04/22/2022) (2) |
| Apr 18, 2022 | 124 | NOTICE OF SERVICE of Defendant RedHill Biopharma Inc.'s Responses and Objections to Plaintiff Aether Therapeutics Inc.'s Notice of 30(b)(6) Deposition filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 04/18/2022) (2) |
| Apr 15, 2022 | 123 | NOTICE OF SERVICE of (1) Non-Party Janet Yancey-Wronas Objections to Defendants Subpoena Duces Tecum and (2) Non-Party Danxin Wangs Objections to Defendants Subpoena Duces Tecum filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 04/15/2022) (2) |
| Apr 13, 2022 | 122 | MOTION for Pro Hac Vice Appearance of Attorney Cedric C. Y. Tan and Christina M. Verone Juliano - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 04/13/2022) (6) |
| Apr 4, 2022 | 121 | SO ORDERED, re 120 Stipulation and [Proposed] Order Regarding Sample Production filed by Aether Therapeutics Inc. Signed by Judge Maryellen Noreika on 4/4/2022. (mdb) (Entered: 04/04/2022) (4) |
| Mar 31, 2022 | 119 | NOTICE OF SERVICE of Subpoenas filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 03/31/2022) (2) |
| Mar 31, 2022 | 120 | STIPULATION and [Proposed] Order Regarding Sample Production by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 03/31/2022) (4) |
| Mar 30, 2022 | 105 | NOTICE to Take Deposition of Todd Krzyszaniak on June 1, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 106 | NOTICE to Take Deposition of Eric Farno on May 18, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (3) |
| Mar 30, 2022 | 107 | NOTICE to Take Deposition of Gal Cohen on May 23, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 108 | NOTICE to Take Deposition of Raymond Wolson on May 17, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (3) |
| Mar 30, 2022 | 109 | NOTICE to Take Deposition of Adi Frish on June 2, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 110 | NOTICE to Take Deposition of Brandon Rawling on May 27, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 111 | NOTICE to Take Deposition of Michael Bentley on May 24, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 112 | NOTICE to Take Deposition of Danielle Abramson on May 30, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 113 | NOTICE to Take Deposition of Rinko Ghosh on May 19, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 114 | NOTICE to Take Deposition of Kevin Brodbeck on May 25, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 115 | NOTICE to Take Deposition of Catherine Datto on May 16, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (3) |
| Mar 30, 2022 | 116 | NOTICE to Take Deposition of Jennifer Riggs-Sauthier on May 26, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 117 | NOTICE to Take Deposition of Nathan Quillen on June 3, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 30, 2022 | 118 | NOTICE to Take Deposition of Rick Scruggs on May 31, 2022 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/30/2022) (4) |
| Mar 23, 2022 | 103 | SO ORDERED re 102 Stipulation and Order Dismissing Claims Regarding U.S. Patent No. 8,883,817. Signed by Judge Maryellen Noreika on 3/23/2022. (dlw) (Entered: 03/23/2022) (2) |
| Mar 23, 2022 | 104 | FURTHER AMDNED Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,713,488 B2. U.S. Patent No. 8,883,817 B2 dropped from suit per Stipulation and Order (See D.I. 102 & 103). (dlw) (Entered: 03/23/2022) (1) |
| Mar 22, 2022 | 102 | STIPULATION and Order Dismissing Claims Regarding U.S. Patent No. 8,883,817 by RedHill Biopharma Inc.. (Joyce, Alexandra) (Entered: 03/22/2022) (2) |
| Mar 10, 2022 | 98 | NOTICE to Take Deposition of Designated Corporate Representative(s) of Defendant AstraZeneca AB and AstraZeneca Pharmaceuticals LP on TBD filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/10/2022) (17) |
| Mar 10, 2022 | 99 | NOTICE to Take Deposition of Designated Corporate Representative(s) of Defendant Daiichi Sankyo, Inc. on TBD filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/10/2022) (14) |
| Mar 10, 2022 | 100 | NOTICE to Take Deposition of Designated Corporate Representative(s) of Defendant Nektar Therapeutics on TBD filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/10/2022) (17) |
| Mar 10, 2022 | 101 | NOTICE to Take Deposition of Designated Corporate Representative(s) of Defendant RedHill Biopharma Inc. on TBD filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 03/10/2022) (16) |
| Mar 7, 2022 | 97 | SO ORDERED re (131 in 1:20-cv-00381-MN, 96 in 1:21-cv-00248-MN) STIPULATION TO EXTEND SCHEDULING ORDER DEADLINES (Set/Reset Scheduling Order Deadlines: Fact Discovery completed by 6/17/2022. Opening Expert Reports due by 7/22/2022. Rebuttal Expert Reports due by 8/19/2022. Reply Expert Reports due by 9/9/2022. Expert Discovery due by 9/30/2022). SEE STIPULATION FOR FURTHER AND COMPELTE DETAILS. Signed by Judge Maryellen Noreika on 3/7/2022. (dlw) (Entered: 03/07/2022) (4) |
| Mar 4, 2022 | 96 | STIPULATION TO EXTEND TIME certain case deadlines to various dates - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 03/04/2022) (4) |
| Mar 1, 2022 | 92 | NOTICE to Take Deposition of Wolfgang Sadee on April 13, 2022 filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 03/01/2022) (2) |
| Mar 1, 2022 | 93 | NOTICE to Take Deposition of Jon Saxe on March 28, 2022 filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 03/01/2022) (2) |
| Mar 1, 2022 | 94 | NOTICE to Take Deposition of Brian Cummings on March 30, 2022 filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 03/01/2022) (2) |
| Mar 1, 2022 | 95 | NOTICE OF SERVICE of of Subpoenas filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 03/01/2022) (11) |
| Feb 28, 2022 | 91 | ORAL ORDER - WHEREAS, on 2/25/2022, consistent with the Scheduling Order, the parties contacted Chambers to request a discovery dispute teleconference date regarding the extension of certain discovery dates and, with that request, attached a proposed stipulation; and WHEREAS, having reviewed the request, the proposed stipulation, and the case docket, IT IS HEREBY ORDERED that the proposed stipulation is GRANTED with the following modifications: (1) the stipulation shall contain a provision(s) for the exchange of final non-infringement and final validity contention; (2) within one week after the exchange of all final contentions (infringement, non-infringement, invalidity, validity), the parties shall file a joint letter confirming that the final contention have not raised any additional claim construction issues; (3) summary judgment and Daubert motions will not be accepted as a matter of course in this case. Instead, the following procedures are hereby adopted: If a SIDE wishes to file any motion(s) for summary judgment in this case, then on or before 10/7/2022, the side may file a single letter of no more than three pages explaining the basis for the motion(s) and what undisputed facts support entry of summary judgment. If a SIDE wishes to file any motion(s) to exclude an expert's opinion (or multiple experts' opinions) pursuant to Daubert, then on or before 10/7/2022, the side may file a separate single letter of no more than three pages, identifying the opinion(s) sought to be excluded and the basis for exclusion. Responses to any such letters may be filed on or before 10/14/2022. Each such responsive letter shall be no more than three pages. No summary judgment or Daubert motions may be filed without obtaining leave from the Court according to these procedures. IT IS FURTHER ORDERED that the parties shall file a stipulation memorializing this oral order on or before 3/7/2022. ORDERED by Judge Maryellen Noreika on 2/28/2022. (dlw) (Entered: 02/28/2022) (0) |
| Feb 16, 2022 | 89 | STIPULATION and [Proposed] Order Regarding Sample Production by RedHill Biopharma Inc.. (Joyce, Alexandra) (Entered: 02/16/2022) (4) |
| Feb 16, 2022 | 90 | SO ORDERED re 89 Stipulation and Order Regarding Sample Production. Signed by Judge Maryellen Noreika on 2/16/2022. (dlw) (Entered: 02/16/2022) (4) |
| Jan 28, 2022 | 88 | NOTICE OF SERVICE of (1) Aether Therapeutics Inc.s Responses and Objections to Defendants Requests for Production (Nos. 164-183) and (2) Aether Therapeutics Inc.s Responses and Objections to Defendant Redhill Biopharma Inc.s First Interrogatories (Nos. 1-7) filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 01/28/2022) (2) |
| Jan 4, 2022 | 85 | STIPULATION and [Proposed] Order Dismissing Claims Regarding U.S. Patent Nos. 9,061,024 and 8,748,448 by RedHill Biopharma Inc.. (Joyce, Alexandra) (Entered: 01/04/2022) (3) |
| Jan 4, 2022 | 86 | SO ORDERED re 85 Stipulation and Order Dismissing Claims Regarding U.S. Patent Nos. 9,061,024 and 8,748,448. Signed by Judge Maryellen Noreika on 1/4/2022. (dlw) (Entered: 01/04/2022) (3) |
| Jan 4, 2022 | 87 | AMENDED Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,713,488 B2; 8,883,817 B2. U.S. Patent Nos. 8,748,448 B2 and 9,061,024 B2 dropped from suit 1/4/2022 per Stipulation and Order (See D.I. 85 & 86). (dlw) (Entered: 01/04/2022) (1) |
| Dec 28, 2021 | 84 | NOTICE OF SERVICE of (1) RedHill's First Interrogatories to Aether Therapeutics Inc. (Nos. 1-7) and (2) RedHill's Requests for Production to Aether Therapeutics Inc. (Nos. 164-183) filed by RedHill Biopharma Inc..(Joyce, Alexandra) (Entered: 12/28/2021) (3) |
| Dec 16, 2021 | 83 | NOTICE OF SERVICE of (1) RedHill Biopharma Inc.'s First Supplemental Paragraph 3 Disclosures and (2) RedHill Biopharma Inc.'s First Supplemental Disclosures Pursuant to Rule 26(A)(1) filed by RedHill Biopharma Inc..(Silver, Daniel) (Entered: 12/16/2021) (2) |
| Dec 14, 2021 | 82 | Official Transcript of Discovery Dispute Teleconference held on 11/08/2021 before Judge Maryellen Noreika. Court Reporter/Transcriber Dale C. Hawkins,Email: Dale_Hawkins@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/4/2022. Redacted Transcript Deadline set for 1/14/2022. Release of Transcript Restriction set for 3/14/2022. (dh) (Entered: 12/14/2021) (22) |
| Dec 8, 2021 | 81 | MOTION for Pro Hac Vice Appearance of Attorney Christopher P. Damitio - filed by RedHill Biopharma Inc.. (Attachments: # 1 Certification for Christopher P. Damitio)(Silver, Daniel) (Entered: 12/08/2021) (Main Document) (2) |
| Dec 8, 2021 | 81 | MOTION for Pro Hac Vice Appearance of Attorney Christopher P. Damitio - filed by RedHill Biopharma Inc.. (Attachments: # 1 Certification for Christopher P. Damitio)(Silver, Daniel) (Entered: 12/08/2021) (Certification for Christopher P. Damitio) (1) |
| Dec 2, 2021 | 80 | SO ORDERED re (79 in 1:21-cv-00248-MN, 115 in 1:20-cv-00381-MN) STIPULATION TO EXTEND certain case deadlines to various dates (Set/Reset Scheduling Order Deadlines: Fact Discovery completed by 4/29/2022. Opening Expert Reports due by 6/17/2022. Rebuttal Expert Reports due by 7/22/2022. Reply Expert Reports due by 8/12/2022. Expert Discovery due by 9/9/2022. Dispositive Motions due by 9/23/2022. Answering Brief due 10/21/2022). Signed by Judge Maryellen Noreika on 12/2/2021. (dlw) (Entered: 12/02/2021) (4) |
| Nov 30, 2021 | 79 | STIPULATION TO EXTEND TIME of certain case deadlines to various dates - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 11/30/2021) (4) |
| Nov 18, 2021 | 78 | NOTICE OF SERVICE of Aether Therapeutics Inc.s Responses and Objections to Defendants Requests for Production (Nos. 145-163) filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 11/18/2021) (2) |
| Nov 9, 2021 | 77 | NOTICE of Withdrawal of Defendants' Motion Without Prejudice by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Nektar Therapeutics, LLC re (104 in 1:20-cv-00381-MN) MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c), (63 in 1:21-cv-00248-MN) MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) (Silver, Daniel) (Entered: 11/09/2021) (3) |
| Nov 8, 2021 | 76 | STIPULATION and Proposed Oder to Extend Time to File Reply Brief in Support of Defendants' Motion for Judgment on the Pleadings on Aether's Claims for Infringement by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP. (Joyce, Alexandra) (Entered: 11/08/2021) (3) |
| Nov 4, 2021 | 73 | MOTION for Pro Hac Vice Appearance of Attorney Kasey E. Koballa - filed by RedHill Biopharma Inc.. (Silver, Daniel) (Entered: 11/04/2021) (3) |
| Nov 4, 2021 | 74 | ANSWERING BRIEF in Opposition re 63 MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) filed by Aether Therapeutics Inc..Reply Brief due date per Local Rules is 11/12/2021. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Stamoulis, Stamatios) (Entered: 11/04/2021) (Main Document) (13) |
| Nov 4, 2021 | 75 | STIPULATION TO EXTEND TIME for Defendant RedHill Biopharma Inc. to file a motion for judgment on the pleadings pursuant to Federal Rule of Civil Procedure 12(c) regarding the validity of the 448 Patent's Certificate of Correction to January 14, 2022 - filed by RedHill Biopharma Inc. (Joyce, Alexandra) Modified on 11/5/2021 (dlw). (Main Document 75 replaced on 11/5/2021) (dlw). (Entered: 11/04/2021) (2) |
| Nov 4, 2021 | 74 | ANSWERING BRIEF in Opposition re 63 MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) filed by Aether Therapeutics Inc..Reply Brief due date per Local Rules is 11/12/2021. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Stamoulis, Stamatios) (Entered: 11/04/2021) (Exhibit 1) (30) |
| Nov 4, 2021 | 74 | ANSWERING BRIEF in Opposition re 63 MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) filed by Aether Therapeutics Inc..Reply Brief due date per Local Rules is 11/12/2021. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Stamoulis, Stamatios) (Entered: 11/04/2021) (Exhibit 2) (3) |
| Nov 2, 2021 | 71 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Discovery Dispute Opening Letter - re (103 in 1:20-cv-00381-MN, 62 in 1:21-cv-00248-MN) Order Setting Teleconference,,. (Attachments: # 1 Exhibit A-D, # 2 Text of Proposed Order)(Silver, Daniel) (Entered: 11/02/2021) (Main Document) (5) |
| Nov 2, 2021 | 72 | Letter to The Honorable Maryellen Noreika from Stamatios Stamoulis regarding Responding to Defendant's Dispute Letter - re 71 Letter. (Attachments: # 1 Exhibit 1)(dlw) (Entered: 11/04/2021) (Main Document) (6) |
| Nov 2, 2021 | 71 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Discovery Dispute Opening Letter - re (103 in 1:20-cv-00381-MN, 62 in 1:21-cv-00248-MN) Order Setting Teleconference,,. (Attachments: # 1 Exhibit A-D, # 2 Text of Proposed Order)(Silver, Daniel) (Entered: 11/02/2021) (Exhibit A-D) (12) |
| Nov 2, 2021 | 71 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Discovery Dispute Opening Letter - re (103 in 1:20-cv-00381-MN, 62 in 1:21-cv-00248-MN) Order Setting Teleconference,,. (Attachments: # 1 Exhibit A-D, # 2 Text of Proposed Order)(Silver, Daniel) (Entered: 11/02/2021) (Text of Proposed Order) (2) |
| Nov 2, 2021 | 72 | Letter to The Honorable Maryellen Noreika from Stamatios Stamoulis regarding Responding to Defendant's Dispute Letter - re 71 Letter. (Attachments: # 1 Exhibit 1)(dlw) (Entered: 11/04/2021) (Exhibit 1) (30) |
| Nov 1, 2021 | 70 | NOTICE OF SERVICE of RedHill Biopharma Inc.'s Response and Objections to Aether Therapeutics Inc.'s Second Set of Requests for Production of Documents and Things (Nos. 25-90) filed by RedHill Biopharma Inc..(Silver, Daniel) (Entered: 11/01/2021) (2) |
| Oct 28, 2021 | 69 | Case referred to mediation.. Signed by Judge Mary Pat Thynge on 10/28/2021. (Taylor, Daniel) (Entered: 10/28/2021) (1) |
| Oct 27, 2021 | 68 | STIPULATION TO EXTEND TIME to respond to Defendants Motion for Judgment on the Pleadings on Aethers Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) to November 4, 2021 - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 10/27/2021) (3) |
| Oct 26, 2021 | 67 | NOTICE OF SERVICE of Redhill Biopharma Inc.'s Responses and Objections to Aether Therapeutics Inc.'s Fourth Set of Requests for the Production of Documents and Things (Nos. 172-173) filed by RedHill Biopharma Inc..(Silver, Daniel) (Entered: 10/26/2021) (2) |
| Oct 20, 2021 | 66 | NOTICE OF SERVICE of Aether Therapeutics Inc.s Fourth Set of Requests for the Production of Documents and Things (No. 172-173) filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 10/20/2021) (2) |
| Oct 19, 2021 | 65 | NOTICE OF SERVICE of Defendants' Requests for Production to Aether Therapeutics Inc., Nos. 145-163 filed by RedHill Biopharma Inc..(Silver, Daniel) (Entered: 10/19/2021) (2) |
| Oct 14, 2021 | 63 | MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) - filed by RedHill Biopharma Inc.. (Attachments: # 1 Text of Proposed Order)(Silver, Daniel) Modified on 10/15/2021 (mdb). (Entered: 10/14/2021) (Main Document) (3) |
| Oct 14, 2021 | 64 | OPENING BRIEF in Support re 63 MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) filed by RedHill Biopharma Inc..Answering Brief/Response due date per Local Rules is 10/28/2021. (Attachments: # 1 Exhibit A1-D)(Silver, Daniel) Modified on 10/15/2021 (mdb). (Entered: 10/14/2021) (Main Document) (17) |
| Oct 14, 2021 | 64 | OPENING BRIEF in Support re 63 MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) filed by RedHill Biopharma Inc..Answering Brief/Response due date per Local Rules is 10/28/2021. (Attachments: # 1 Exhibit A1-D)(Silver, Daniel) Modified on 10/15/2021 (mdb). (Entered: 10/14/2021) (Exhibit A1-D) (30) |
| Oct 14, 2021 | 63 | MOTION for Judgment on the Pleadings on Aether's Claims for Infringement of U.S. Patent Nos. 8,883,817, 9,061,024, and 8,748,448 Under Federal Rule of Civil Procedure 12(c) - filed by RedHill Biopharma Inc.. (Attachments: # 1 Text of Proposed Order)(Silver, Daniel) Modified on 10/15/2021 (mdb). (Entered: 10/14/2021) (Text of Proposed Order) (2) |
| Oct 4, 2021 | 62 | ORAL ORDER Setting Teleconference: Having been advised by the parties of their inability to resolve a discovery dispute, IT IS HEREBY ORDERED that a Telephone Conference is set for 11/8/2021 at 12:30 PM before Judge Maryellen Noreika. The opening letter(s) (not to exceed three (3) pages) is due no later than 11/2/2021. The answering letter(s) (not to exceed three (3) pages) is due no later than 11/3/2021. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/4/2021. (dlw) (Entered: 10/04/2021) (0) |
| Oct 1, 2021 | 61 | NOTICE OF SERVICE of Aether Therapeutics Inc.s Second Set of Requests for the Production of Documents and Things (Nos. 25-90) filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 10/01/2021) (2) |
| Sep 23, 2021 | 60 | STIPULATION TO EXTEND TIME the Deadline to File a Motion for Judgment on the Pleadings Pursuant to Federal Rule of Civil Procedure 12(c) regarding the Vaidity of the '448 Patent's Certificate of Correction to November 8, 2021 - filed by RedHill Biopharma Inc.. (Joyce, Alexandra) (Entered: 09/23/2021) (2) |
| Sep 17, 2021 | 58 | Official Transcript of Markman Hearing held on 08/30/2021 before Judge Maryellen Noreika. Court Reporter/Transcriber Dale C. Hawkins,Email: Dale_Hawkins@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 10/8/2021. Redacted Transcript Deadline set for 10/18/2021. Release of Transcript Restriction set for 12/16/2021. (dh) (Entered: 09/17/2021) (70) |
| Sep 17, 2021 | 59 | MEMORANDUM ORDER REGARDING CLAIM CONSTRUCTION. Signed by Judge Maryellen Noreika on 9/17/2021. Associated Cases: 1:20-cv-00381-MN, 1:21-cv-00248-MN(mdb) (Entered: 09/17/2021) (13) |
| Sep 2, 2021 | 57 | MOTION for Pro Hac Vice Appearance of Attorney Michael J. Barresi - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 09/02/2021) (5) |
| Aug 27, 2021 | 56 | Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis regarding Improper Submission of Additional Extrinsic Evidence - re (95 in 1:20-cv-00381-MN, 55 in 1:21-cv-00248-MN) Letter,. (Stamoulis, Stamatios) (Entered: 08/27/2021) (2) |
| Aug 26, 2021 | 55 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Transcripts of Depositions of Experts for Use at Markman Hearing. (Attachments: # 1 Transcript of Deposition of Thomas E. Prizinzano, Ph.D., # 2 Transcript of Deposition of David W.C. MacMillan, Ph.D.)(Silver, Daniel) (Entered: 08/26/2021) (Main Document) (1) |
| Aug 26, 2021 | 55 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Transcripts of Depositions of Experts for Use at Markman Hearing. (Attachments: # 1 Transcript of Deposition of Thomas E. Prizinzano, Ph.D., # 2 Transcript of Deposition of David W.C. MacMillan, Ph.D.)(Silver, Daniel) (Entered: 08/26/2021) (Transcript of Deposition of Thomas E. Prizinzano, Ph.D.) (30) |
| Aug 26, 2021 | 55 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Transcripts of Depositions of Experts for Use at Markman Hearing. (Attachments: # 1 Transcript of Deposition of Thomas E. Prizinzano, Ph.D., # 2 Transcript of Deposition of David W.C. MacMillan, Ph.D.)(Silver, Daniel) (Entered: 08/26/2021) (Transcript of Deposition of David W.C. MacMillan, Ph.D.) (26) |
| Aug 20, 2021 | 53 | NOTICE to Take Deposition of Dr. Thomas Prisinzano on August 25, 2021 filed by Aether Therapeutics Inc..(Joyce, Alexandra) (Entered: 08/20/2021) (2) |
| Aug 20, 2021 | 54 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Agreement Not to Present Live Testimony at the Markman Hearing. (Silver, Daniel) (Entered: 08/20/2021) (1) |
| Aug 16, 2021 | 52 | ORAL ORDER re (50 in 1:21-cv-00248-MN, 90 in 1:20-cv-00381-MN) Letter - IT IS HEREBY ORDERED that the Court is setting aside 1.5 hours for the 8/30/2021 Markman hearing with the time split equally between the parties to use for argument and, if the parties choose, for live testimony. The hearing will take place in Courtroom 4A. Any slide presentations the parties wish to use during the hearing shall be emailed (in PDF format) to MN_civil@ded.uscourts.gov no later than 24 hours prior to the hearing. The parties, however, may agree upon a different time to exchange their respective slides. ORDERED by Judge Maryellen Noreika on 8/16/2021. (dlw) (Entered: 08/16/2021) (0) |
| Aug 13, 2021 | 48 | JOINT CLAIM CONSTRUCTION BRIEF filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 08/13/2021) (30) |
| Aug 13, 2021 | 49 | APPENDIX re (88 in 1:20-cv-00381-MN) Joint Claim Construction Brief, (48 in 1:21-cv-00248-MN) Joint Claim Construction Brief by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1-3, # 2 Exhibit 4-20, # 3 Exhibit 21-28, # 4 Exhibit 29-35)(Stamoulis, Stamatios) (Main Document 49 replaced on 8/17/2021) (dlw). (Attachment 3 replaced on 8/17/2021) (dlw). (Entered: 08/13/2021) (Main Document) (4) |
| Aug 13, 2021 | 50 | Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis and Alexandra M. Joyce regarding Time Request for Oral Argument at Claim Construction Hearing. (Stamoulis, Stamatios) (Entered: 08/13/2021) (2) |
| Aug 13, 2021 | 51 | Letter to The Honorable Maryelle Noreika from Stamatios Stamoulis regarding Confirmation of Submission of Tutorial. (Stamoulis, Stamatios) (Entered: 08/13/2021) (1) |
| Aug 13, 2021 | 49 | APPENDIX re (88 in 1:20-cv-00381-MN) Joint Claim Construction Brief, (48 in 1:21-cv-00248-MN) Joint Claim Construction Brief by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1-3, # 2 Exhibit 4-20, # 3 Exhibit 21-28, # 4 Exhibit 29-35)(Stamoulis, Stamatios) (Main Document 49 replaced on 8/17/2021) (dlw). (Attachment 3 replaced on 8/17/2021) (dlw). (Entered: 08/13/2021) (Exhibit 1-3) (30) |
| Aug 13, 2021 | 49 | APPENDIX re (88 in 1:20-cv-00381-MN) Joint Claim Construction Brief, (48 in 1:21-cv-00248-MN) Joint Claim Construction Brief by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1-3, # 2 Exhibit 4-20, # 3 Exhibit 21-28, # 4 Exhibit 29-35)(Stamoulis, Stamatios) (Main Document 49 replaced on 8/17/2021) (dlw). (Attachment 3 replaced on 8/17/2021) (dlw). (Entered: 08/13/2021) (Exhibit 4-20) (30) |
| Aug 13, 2021 | 49 | APPENDIX re (88 in 1:20-cv-00381-MN) Joint Claim Construction Brief, (48 in 1:21-cv-00248-MN) Joint Claim Construction Brief by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1-3, # 2 Exhibit 4-20, # 3 Exhibit 21-28, # 4 Exhibit 29-35)(Stamoulis, Stamatios) (Main Document 49 replaced on 8/17/2021) (dlw). (Attachment 3 replaced on 8/17/2021) (dlw). (Entered: 08/13/2021) (Exhibit 21-28) (30) |
| Aug 13, 2021 | 49 | APPENDIX re (88 in 1:20-cv-00381-MN) Joint Claim Construction Brief, (48 in 1:21-cv-00248-MN) Joint Claim Construction Brief by Aether Therapeutics Inc.. (Attachments: # 1 Exhibit 1-3, # 2 Exhibit 4-20, # 3 Exhibit 21-28, # 4 Exhibit 29-35)(Stamoulis, Stamatios) (Main Document 49 replaced on 8/17/2021) (dlw). (Attachment 3 replaced on 8/17/2021) (dlw). (Entered: 08/13/2021) (Exhibit 29-35) (30) |
| Aug 11, 2021 | 46 | NOTICE to Take Deposition of David W.C. MacMillan on August 17, 2021 filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 08/11/2021) (3) |
| Aug 11, 2021 | 47 | MOTION for Pro Hac Vice Appearance of Attorney Michael A. Siem, Christopher J. Belter, Lynn Lehnert, Kenneth A. Matuszewski, and Anthony M. Kroese - filed by Aether Therapeutics Inc.. (Stamoulis, Stamatios) (Entered: 08/11/2021) (9) |
| Aug 6, 2021 | 45 | NOTICE OF SERVICE of Defendants Sur-Reply Claim Construction Brief and Supporting Documents filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Nektar Therapeutics, LLC.(Silver, Daniel) (Entered: 08/06/2021) (3) |
| Jul 29, 2021 | 44 | NOTICE OF SERVICE of Plaintiff Aether Therapeutics Inc.s Reply Claim Construction Brief filed by Aether Therapeutics Inc..(Stamoulis, Stamatios) (Entered: 07/29/2021) (3) |
| Jul 26, 2021 | 43 | ORAL ORDER - WHEREAS, consistent with the Scheduling Order, the parties contacted Chambers to request a discovery dispute teleconference for a dispute that arose from Plaintiff submitting an expert declaration in support of its claim constructions but not willing to produce the expert for a deposition, and WHEREAS, it is the Court's policy that if a party provides an expert declaration during claim construction proceedings, that party must make the expert available for deposition prior to the claim construction hearing. THEREFORE, IT IS HEREBY ORDERED that Plaintiff shall produce the expert for deposition prior to the 8/30/2021 claim construction hearing. No additional claim construction briefing or arguments may be submitted after the Joint Claim Construction brief is filed absent leave of Court. ORDERED by Judge Maryellen Noreika on 7/26/2021. (dlw) (Entered: 07/26/2021) (0) |
| Jul 22, 2021 | 42 | NOTICE to Take Deposition of Dr. Thomas Prisinzano on Monday, August 2, 2021 filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Nektar Therapeutics, LLC.(Silver, Daniel) (Entered: 07/22/2021) (2) |
| Jul 15, 2021 | 41 | Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis regarding Responding to Defendant's July 13, 2021 Letter - re (39 in 1:21-cv-00248-MN) Letter. (Stamoulis, Stamatios) (Entered: 07/15/2021) (2) |
| Jul 14, 2021 | 40 | REDACTED VERSION of 37 Answer to Amended Complaint by RedHill Biopharma Inc.. (Silver, Daniel) (Entered: 07/14/2021) (30) |
| Jul 13, 2021 | 39 | Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Responsive Letter - re (38 in 1:21-cv-00248-MN, 79 in 1:20-cv-00381-MN) Letter. (Silver, Daniel) (Entered: 07/13/2021) (4) |
| Jul 9, 2021 | 38 | Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis regarding Requesting Assistance Regarding Claim Construction Issue. (Attachments: # 1 Exhibit A)(Stamoulis, Stamatios) (Entered: 07/09/2021) (Main Document) (3) |
| Jul 9, 2021 | 38 | Letter to the Honorable Maryellen Noreika from Stamatios Stamoulis regarding Requesting Assistance Regarding Claim Construction Issue. (Attachments: # 1 Exhibit A)(Stamoulis, Stamatios) (Entered: 07/09/2021) (Exhibit A) (9) |
| Jul 6, 2021 | 37 | [SEALED] ANSWER and Defenses to Amended Complaint, re: 33 Amended Complaint by RedHill Biopharma Inc. (Attachments: # 1 Exhibits 1-20, # 2 Certificate of Service)(Silver, Daniel) Modified on 7/6/2021 (dlw). (Entered: 07/06/2021) (0) |
| Jun 29, 2021 | 35 | STIPULATION TO EXTEND TIME Defendant's Deadline to Answer, Move or Otherwise Respond to the First Amended Complaint to July 6, 2021 - filed by RedHill Biopharma Inc.. (Silver, Daniel) (Entered: 06/29/2021) (2) |
| Jun 29, 2021 | 36 | NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief and supporting documents filed by RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Nektar Therapeutics, LLC.(Silver, Daniel) (Entered: 06/29/2021) (3) |
| Jun 16, 2021 | 34 | NOTICE OF SERVICE of RedHill Biopharma Inc.'s Responses and Objections to Aether Therapeutics Inc.'s Second Set of Interrogatories (No. 9) filed by RedHill Biopharma Inc..(Silver, Daniel) (Entered: 06/16/2021) (2) |
| Jun 8, 2021 | 33 | Amended Complaint* (1) |
| Feb 22, 2021 | 1 | Complaint* (1) |
